Valiant Laboratories Ltd
Valiant Laboratories Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Valiant Laboratories Ltd Q2 FY27 key numbers
- Revenue
- Quarter Revenue (Consolidated): Rs. 11,677.32 Lakhs for the quarter ended 30th Sep 2026.
As stated in Valiant Laboratories Ltd's Q2 FY27 results statement · published 2 Nov 2026. Reported figures, not investment advice.
Based on Valiant Laboratories Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Quarter Revenue (Consolidated): Rs. EBITDA for the quarter ended 30-Sep-2026: - Reported profit before exceptional item & tax (approximate EBITDA) is Rs.
From Valiant Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 2 Nov 2026.
Revenue & Sales Performance
- Quarter Revenue (Consolidated): Rs. 11,677.32 Lakhs for the quarter ended 30th Sep 2026.
- Quarter Revenue Previous Year: Rs. 4,620.24 Lakhs for the quarter ended 30th Sep 2025.
- Year-on-Year Revenue Growth: Approximately 152.8% increase (from Rs. 4,620.24 Lakhs to Rs. 11,677.32 Lakhs).
- Standalone Revenue for the Quarter: Rs. 7,243.40 Lakhs for 30th Sep 2026 vs Rs. 4,598.77 Lakhs in 30th Sep 2025 (about 57.5% increase).
Profitability & Margins
See what Valiant Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Valiant Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Valiant Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Valiant Laboratories Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹115 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
Others in Pharmaceuticals & Biotechnology this season
- SPARC (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026, is ₹3,003 lakhs, up from ₹786 lakhs in the quarter ended September 30, 2025. Key results state
- Wockhardt Ltd (Q2 FY27)
969 crore, up from Rs. Key results statement takeaways from Wockhardt Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- JFL Life (Q2 FY27)
This represents a year-on-year increase of approximately 96% in revenue for the quarter. Key results statement takeaways from JFL Life Sciences Ltd's Q2 FY27 ea
- P & G Health Ltd (Q2 FY27)
Revenue from Operations for the quarter ended September 30, 2026, is ₹38,249 lakhs (Page 4). Key results statement takeaways from Procter & Gamble Health Ltd's
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Valiant Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Valiant Laboratories Ltd Q2 FY27 results?
Quarter Revenue (Consolidated): Rs. EBITDA for the quarter ended 30-Sep-2026: - Reported profit before exceptional item & tax (approximate EBITDA) is Rs.
What is Valiant Laboratories Ltd share price analysis?
Valiant Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 42.7 with a market cap of ₹683 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Valiant Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.